https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-acquires-nautilus-pharmacy-assets BiopharmaWatch en 2026-09-01T20:30:00.000Z Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy https://www.biopharmawatch.com/news/BRVE/braveheart-bio-cantor-global-healthcare-conference BiopharmaWatch en 2026-09-01T20:30:00.000Z Braveheart Bio to Participate in Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/CLLS/cellectis-participation-upcoming-investor-conferences BiopharmaWatch en 2026-09-01T20:30:00.000Z Cellectis Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PACS/pacs-group-acquires-32-facilities-florida BiopharmaWatch en 2026-09-01T20:15:00.000Z PACS Group to Acquire Operations of 32 Facilities Across Florida and Closes on Additional Previously Announced Eduro Facilities https://www.biopharmawatch.com/news/ANAB/anaptys-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-01T20:15:00.000Z Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/MYO/myomo-presents-hc-wainwright-investment-conference BiopharmaWatch en 2026-09-01T20:05:00.000Z Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-investor-conferences-september BiopharmaWatch en 2026-09-01T20:05:00.000Z Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September https://www.biopharmawatch.com/news/SI/shoulder-innovations-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-01T20:05:00.000Z Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference https://www.biopharmawatch.com/news/INO/inovio-participate-investor-conferences-september-2026 BiopharmaWatch en 2026-09-01T20:05:00.000Z INOVIO to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-01T20:05:00.000Z Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/BBOT/bbot-participate-investor-healthcare-conferences BiopharmaWatch en 2026-09-01T20:05:00.000Z BBOT to Participate in Upcoming Investor Healthcare Conferences https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-09-01T20:05:00.000Z Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences https://www.biopharmawatch.com/news/SANA/sana-biotechnology-september-2026-investor-conferences BiopharmaWatch en 2026-09-01T20:05:00.000Z Sana Biotechnology to Present at September 2026 Investor Conferences https://www.biopharmawatch.com/news/SGHT/sight-sciences-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-01T20:05:00.000Z Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15 https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-01T20:05:00.000Z Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CLGN/collplant-reverse-share-split-september-2026 BiopharmaWatch en 2026-09-01T20:01:00.000Z COLLPLANT ANNOUNCES REVERSE SHARE SPLIT https://www.biopharmawatch.com/news/ARVN/arvinas-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-09-01T20:01:00.000Z Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RMT/royce-micro-cap-trust-third-quarter-distribution BiopharmaWatch en 2026-09-01T19:33:06.575Z Royce Micro-Cap Trust, Inc. (NYSE-RMT) declares Third Quarter Common Stock Distribution of $0.23 Per Share https://www.biopharmawatch.com/news/SBC/sbc-medical-investor-conferences-september-2026 BiopharmaWatch en 2026-09-01T17:35:00.000Z SBC Medical to Participate in Several Upcoming Investor Conferences in September 2026 https://www.biopharmawatch.com/news/KYTX/kyverna-miv-cel-safety-profile-update BiopharmaWatch en 2026-09-01T17:00:00.000Z Company Statement on Miv-cel's Favorable Safety Profile https://www.biopharmawatch.com/news/ONC/beone-medicines-partnership-us-government-cancer-therapy BiopharmaWatch en 2026-09-01T16:46:00.000Z شركة BeOne Medicines تعلن عن إبرام اتفاقية طوعية مع الحكومة الأمريكية لتعزيز وتوسيع إمكانية الحصول على علاجات السرطان المُبتكرة https://www.biopharmawatch.com/news/ONC/beone-medicines-us-agreement-cancer-drugs BiopharmaWatch en 2026-09-01T16:46:00.000Z BeOne Medicines anuncia acordo voluntário com o governo dos EUA para expandir o acesso a medicamentos inovadores contra o câncer https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs BiopharmaWatch en 2026-09-01T16:46:00.000Z BeOne Medicines anuncia un acuerdo voluntario con el Gobierno de EE. UU. para ampliar el acceso a medicamentos innovadores contra el cáncer https://www.biopharmawatch.com/news/ONC/beone-medicines-us-agreement-oncology-drugs BiopharmaWatch en 2026-09-01T16:45:00.000Z Riassunto: BeOne Medicines annuncia un accordo volontario con l'Amministrazione degli Stati Uniti per ampliare l'accesso a farmaci oncologici innovativi https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs BiopharmaWatch en 2026-09-01T16:45:00.000Z BeOne Medicines gibt freiwillige Vereinbarung mit der US-Regierung bekannt, um den Zugang zu innovativen Krebsmedikamenten zu erweitern https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-drugs BiopharmaWatch en 2026-09-01T16:45:00.000Z Samenvatting: BeOne Medicines kondigt vrijwillige overeenkomst met Amerikaanse overheid aan om toegang tot innovatieve kankermedicijnen te vergroten https://www.biopharmawatch.com/news/AZN/oral-pcsk9-inhibitor-market-growth-2026 BiopharmaWatch en 2026-09-01T14:31:00.000Z The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-zihiera BiopharmaWatch en 2026-09-01T14:21:00.000Z BeOne Medicines تعلن عن بيانات جديدة من المرحلة الثالثة حول معدلات البقاء على قيد الحياة، تعزّز الفوائد العلاجية للأنظمة الدوائية المحتوية على ZIIHERA لدى مرضى سرطان المعدة والمريء الإيجابي لمستقبل HER2+ في خط العلاج الأول https://www.biopharmawatch.com/news/LLY/lilly-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-01T14:00:00.000Z Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CODX/co-diagnostics-vector-smart-international-expansion BiopharmaWatch en 2026-09-01T13:30:00.000Z Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base https://www.biopharmawatch.com/news/PHGE/biomx-changes-name-to-tessera-defense BiopharmaWatch en 2026-09-01T13:25:00.000Z BiomX Inc. to Become Tessera Defense and Homeland Security Inc. https://www.biopharmawatch.com/news/LEXX/lexaria-receives-2-6-million-tax-rebate BiopharmaWatch en 2026-09-01T13:21:00.000Z Lexaria Receives USD$2.6 Million Tax Rebate Payment https://www.biopharmawatch.com/news/BMRN/biomarin-acquires-alesta-therapeutics BiopharmaWatch en 2026-09-01T13:05:00.000Z BioMarin Announces Close of the Alesta Therapeutics Acquisition https://www.biopharmawatch.com/news/SYK/stryker-fda-authorized-surgical-application-apple-vision-pro BiopharmaWatch en 2026-09-01T13:05:00.000Z Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center https://www.biopharmawatch.com/news/VRTX/vertex-acquisition-crinetics-expansion-leadership BiopharmaWatch en 2026-09-01T13:03:00.000Z Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team https://www.biopharmawatch.com/news/BLLN/billiontoone-launches-northstar-origin-liquid-biopsy-test BiopharmaWatch en 2026-09-01T13:00:00.000Z BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin https://www.biopharmawatch.com/news/NXG/nxg-nextgen-infrastructure-income-fund-distributions BiopharmaWatch en 2026-09-01T12:40:52.842Z NXG NextGen Infrastructure Income Fund (NYSE: NXG) Announces Distributions https://www.biopharmawatch.com/news/SRV/nxg-cushing-midstream-energy-fund-distributions BiopharmaWatch en 2026-09-01T12:40:35.420Z NXG Cushing® Midstream Energy Fund (NYSE: SRV) Announces Distributions https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-98-percent-accuracy-study BiopharmaWatch en 2026-09-01T12:31:00.000Z Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-01T12:30:00.000Z Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference https://www.biopharmawatch.com/news/DXCM/dexcom-upcoming-conference-presentation BiopharmaWatch en 2026-09-01T12:30:00.000Z Dexcom Announces Upcoming Conference Presentation https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-01T12:30:00.000Z Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/SDGR/schrodinger-presents-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-01T12:30:00.000Z Schrödinger to Present at Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/FBLG/fibrobiologics-new-patent-degenerative-disc-disease BiopharmaWatch en 2026-09-01T12:30:00.000Z FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media https://www.biopharmawatch.com/news/AMIX/autonomix-medical-abstracts-cirse-2026 BiopharmaWatch en 2026-09-01T12:30:00.000Z Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 https://www.biopharmawatch.com/news/MDAI/spectral-ai-presentation-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-01T12:30:00.000Z Spectral AI to Present at H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-september-october-2026-conference-schedule BiopharmaWatch en 2026-09-01T12:30:00.000Z Conexeu Sciences Sets September and October 2026 Conference Schedule https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-appoints-dr-will-charlton-cmo BiopharmaWatch en 2026-09-01T12:30:00.000Z Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-private-placement-15-million BiopharmaWatch en 2026-09-01T12:30:00.000Z Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-01T12:30:00.000Z CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/BMRA/biomerica-fiscal-2026-financial-results BiopharmaWatch en 2026-09-01T12:19:00.000Z Biomerica Reports Fiscal 2026 Year-End Financial Results https://www.biopharmawatch.com/news/MDT/cornerstone-robotics-medtronic-partnership-robotic-surgery BiopharmaWatch en 2026-09-01T12:17:00.000Z Cornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery https://www.biopharmawatch.com/news/APPT/apptly-koning-partnership-breast-imaging BiopharmaWatch en 2026-09-01T12:06:14.748Z Apptly and Koning Announce Strategic Partnership to Expand Patient Access to Non-Compression 3D Breast Imaging https://www.biopharmawatch.com/news/BFLY/butterfly-network-merge-labs-partnership-bci BiopharmaWatch en 2026-09-01T12:05:00.000Z Merge Labs and Butterfly Network Partner to Advance Ultrasound-Based Brain-Computer Interfaces https://www.biopharmawatch.com/news/GH/guardant-health-shield-blood-test-carelon-coverage BiopharmaWatch en 2026-09-01T12:05:00.000Z Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening https://www.biopharmawatch.com/news/VIVS/vivosim-labs-rat-liver-model-namkind-platform BiopharmaWatch en 2026-09-01T12:05:00.000Z VivoSim Labs to Add Rat Liver Model to NAMkind Platform https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-fraxel-ftx-australia BiopharmaWatch en 2026-09-01T12:01:00.000Z Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia https://www.biopharmawatch.com/news/ABSI/absci-participate-upcoming-investor-conferences BiopharmaWatch en 2026-09-01T12:00:31.000Z Absci to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-advances-mira-55-ind BiopharmaWatch en 2026-09-01T12:00:00.000Z MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND https://www.biopharmawatch.com/news/INCY/incyte-to-present-at-investor-conferences BiopharmaWatch en 2026-09-01T12:00:00.000Z Incyte to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/GNPX/andelyn-biosciences-genprex-diabetes-gene-therapy BiopharmaWatch en 2026-09-01T12:00:00.000Z Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z Scribe Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-investor-meetings-wells-fargo-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston https://www.biopharmawatch.com/news/VOR/vor-bio-participate-september-conferences BiopharmaWatch en 2026-09-01T12:00:00.000Z Vor Bio To Participate in Upcoming September Conferences https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-september-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z Dianthus Therapeutics to Participate in Three Investor Conferences During September https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-01T12:00:00.000Z Nurix Therapeutics to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-wells-fargo-conference BiopharmaWatch en 2026-09-01T12:00:00.000Z Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/PMN/promis-neurosciences-september-conferences-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September https://www.biopharmawatch.com/news/CABA/cabaletta-bio-investor-conferences-2026 BiopharmaWatch en 2026-09-01T12:00:00.000Z Cabaletta Bio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-advancement BiopharmaWatch en 2026-09-01T12:00:00.000Z bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cyfendus-anthrax-vaccine-contract BiopharmaWatch en 2026-09-01T11:55:00.000Z Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) https://www.biopharmawatch.com/news/KALA/kala-virotek-exclusive-distribution-partnership BiopharmaWatch en 2026-09-01T11:45:00.000Z Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program https://www.biopharmawatch.com/news/CMND/clearmind-phase-iia-trial-cmnd-100-aud BiopharmaWatch en 2026-09-01T11:37:00.000Z Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled https://www.biopharmawatch.com/news/DCGO/docgo-participation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-01T11:35:00.000Z DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/BIIB/stoke-biogen-eec-zorevunersen-dravet-syndrome BiopharmaWatch en 2026-09-01T11:30:36.000Z Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-01T11:30:00.000Z Faeth Therapeutics to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-immunotherapy-colorectal-cancer BiopharmaWatch en 2026-09-01T11:30:00.000Z Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy https://www.biopharmawatch.com/news/NRC/brain-aneurysm-awareness-month-2026 BiopharmaWatch en 2026-09-01T11:30:00.000Z Brain Aneurysm Foundation Marks Brain Aneurysm Awareness Month with National Research, Education and Community Initiatives https://www.biopharmawatch.com/news/STOK/stoke-biogen-eec-zorevunersen-dravet-syndrome BiopharmaWatch en 2026-09-01T11:30:00.000Z Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) https://www.biopharmawatch.com/news/ALMS/alumis-envudeucitinib-phase-2b-trial-results BiopharmaWatch en 2026-09-01T11:30:00.000Z Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE) https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-paxalisib-breast-cancer-trial-expansion BiopharmaWatch en 2026-09-01T11:15:00.000Z Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer https://www.biopharmawatch.com/news/KURA/kura-oncology-investor-conferences-september-2026 BiopharmaWatch en 2026-09-01T11:15:00.000Z Kura Oncology to Participate in Three Investor Conferences in September https://www.biopharmawatch.com/news/USNA/usana-ceo-kevin-guest-service-others BiopharmaWatch en 2026-09-01T11:06:00.000Z USANA CEO Kevin Guest Calls on People to Find a Way to Serve Others, Then Act https://www.biopharmawatch.com/news/NEO/neogenomics-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-01T11:05:00.000Z NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-01T11:05:00.000Z Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/OCGN/ocugen-phase-3-trial-ocu410-geographic-atrophy BiopharmaWatch en 2026-09-01T11:02:00.000Z Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration https://www.biopharmawatch.com/news/IVVD/invivyd-appoints-marc-elia-ceo-vyd2311-studies-update BiopharmaWatch en 2026-09-01T11:01:00.000Z Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-investor-scientific-conferences-2026 BiopharmaWatch en 2026-09-01T11:00:38.000Z Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-eric-foster-appointment BiopharmaWatch en 2026-09-01T11:00:26.000Z Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-september-investor-conferences BiopharmaWatch en 2026-09-01T11:00:00.000Z Enanta Pharmaceuticals to Participate in September Investor Conferences https://www.biopharmawatch.com/news/AZN/astrazeneca-global-license-agreement-zegfrov BiopharmaWatch en 2026-09-01T11:00:00.000Z AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer https://www.biopharmawatch.com/news/ACET/adicet-bio-prula-cel-study-completion BiopharmaWatch en 2026-09-01T11:00:00.000Z Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update https://www.biopharmawatch.com/news/UTHR/united-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-09-01T11:00:00.000Z United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences https://www.biopharmawatch.com/news/HROW/harrow-participate-investor-conferences-september-2026 BiopharmaWatch en 2026-09-01T11:00:00.000Z Harrow to Participate in Three Investor Conferences in September https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-3-verekitug-asthma-crsnp BiopharmaWatch en 2026-09-01T11:00:00.000Z Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-phase-1-2-solara-trial-bh-30643 BiopharmaWatch en 2026-09-01T11:00:00.000Z BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-kt-621-presentations-european-congresses BiopharmaWatch en 2026-09-01T11:00:00.000Z Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-01T11:00:00.000Z Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AXGN/axogen-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-01T11:00:00.000Z Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-01T11:00:00.000Z Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-participate-2026-cantor-conference BiopharmaWatch en 2026-09-01T11:00:00.000Z Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-participate-cantor-healthcare-conference BiopharmaWatch en 2026-09-01T11:00:00.000Z Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/BLCO/women-dont-recognize-dry-eye-perimenopause-menopause BiopharmaWatch en 2026-09-01T10:58:00.000Z Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds https://www.biopharmawatch.com/news/WGS/genedx-ceo-katherine-stueland-fierce-50-honoree BiopharmaWatch en 2026-09-01T10:55:00.000Z GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree https://www.biopharmawatch.com/news/MMED/minimed-strong-start-fiscal-year-2027-growth-acceleration BiopharmaWatch en 2026-09-01T10:45:00.000Z MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration https://www.biopharmawatch.com/news/MDT/medtronic-q1-fiscal-2027-results-guidance BiopharmaWatch en 2026-09-01T10:45:00.000Z Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance https://www.biopharmawatch.com/news/ENOV/ecential-robotics-binding-offer-enovis BiopharmaWatch en 2026-09-01T10:45:00.000Z eCential Robotics Announces Binding Offer from Enovis https://www.biopharmawatch.com/news/MDT/medtronic-partnership-cornerstone-robotics-surgery BiopharmaWatch en 2026-09-01T10:40:00.000Z Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery https://www.biopharmawatch.com/news/RFL/greater-boston-urology-expansion BiopharmaWatch en 2026-09-01T10:39:00.000Z Dr. Akash Sharma and Dr. Rafael Tua-Caraccia Join Greater Boston Urology, an Affiliate of U.S. Urology Partners https://www.biopharmawatch.com/news/CMPS/compass-pathways-2026-cantor-conference BiopharmaWatch en 2026-09-01T10:30:00.000Z Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026 https://www.biopharmawatch.com/news/MDT/medtronic-invests-pi-cardia-accelerate-tavr-innovation BiopharmaWatch en 2026-09-01T10:30:00.000Z Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR https://www.biopharmawatch.com/news/TECH/bio-techne-science-based-targets-validation-climate-goals BiopharmaWatch en 2026-09-01T10:30:00.000Z Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals https://www.biopharmawatch.com/news/IMUX/immunic-appoints-chitrang-dave-cddo BiopharmaWatch en 2026-09-01T10:30:00.000Z Immunic Appoints Chitrang Davé as Chief Data and Digital Officer https://www.biopharmawatch.com/news/ENOV/enovis-acquires-ecential-robotics-surgical-innovation BiopharmaWatch en 2026-09-01T10:30:00.000Z Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics https://www.biopharmawatch.com/news/NUMIF/numinus-wellness-corporate-update-september-2026 BiopharmaWatch en 2026-09-01T10:04:46.602Z Numinus Wellness Inc. Provides Corporate Update https://www.biopharmawatch.com/news/HEAL/holy-crap-amazon-us-rollout-protein-innovations BiopharmaWatch en 2026-09-01T10:04:35.572Z Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations https://www.biopharmawatch.com/news/ONC/beone-medicines-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-01T10:00:00.000Z BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference https://www.biopharmawatch.com/news/NTRA/natera-signatera-mrd-assessment-lymphoma-validation BiopharmaWatch en 2026-09-01T10:00:00.000Z New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-presentation-wells-fargo-conference BiopharmaWatch en 2026-09-01T10:00:00.000Z Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-london-investor-rd-day-september-2026 BiopharmaWatch en 2026-09-01T10:00:00.000Z IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/TELO/3rd-international-conference-womens-health-breast-cancer BiopharmaWatch en 2026-09-01T07:45:49.000Z 3rd International Conference on Women’s Health and Breast Cancer https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-09-01T07:16:19.006Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-09-01T07:15:55.843Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-september-2026 BiopharmaWatch en 2026-09-01T07:15:28.766Z FDA Calendar September 2026: A Critical Look at Upcoming Approvals https://www.biopharmawatch.com/news/NVS/novartis-remibrutinib-phase-iii-results BiopharmaWatch en 2026-09-01T05:15:00.000Z Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials https://www.biopharmawatch.com/news/YDES/yd-bio-revenue-growth-2026 BiopharmaWatch en 2026-09-01T03:46:48.000Z YD Bio 公布截至2026年6月30日止六個月財務業績 https://www.biopharmawatch.com/news/PMVP/pmv-pharma-pricing-50-million-public-offering BiopharmaWatch en 2026-09-01T03:03:00.000Z PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities https://www.biopharmawatch.com/news/ADMA/berger-montague-investigates-adma-biologics-board BiopharmaWatch en 2026-09-01T02:39:17.085Z Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-offering BiopharmaWatch en 2026-09-01T00:48:10.980Z BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/ROVA/altrova-health-q3-fiscal-2026-results BiopharmaWatch en 2026-09-01T00:42:34.571Z Altrova Health Reports Third Quarter Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/DTR/diagnostear-technologies-private-placement-units BiopharmaWatch en 2026-09-01T00:42:23.565Z DiagnosTear Technologies Inc. Announces Private Placement of Units https://www.biopharmawatch.com/news/CHER/cheelcare-fiscal-2026-results-curio-update BiopharmaWatch en 2026-09-01T00:42:10.675Z Cheelcare Announces Fourth Quarter and Fiscal 2026 Financial Results and Provides Curio Update https://www.biopharmawatch.com/news/TLT/theralase-releases-q2-2026-financial-statements BiopharmaWatch en 2026-09-01T00:40:37.538Z Theralase(R) Releases Q2 2026 Financial Statements https://www.biopharmawatch.com/news/SHRX/sharp-therapeutics-h1-2026-results-update BiopharmaWatch en 2026-09-01T00:40:24.537Z Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update https://www.biopharmawatch.com/news/DTC/defence-therapeutics-expands-radiopharmaceutical-strategy BiopharmaWatch en 2026-09-01T00:40:11.365Z Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs https://www.biopharmawatch.com/news/MRNA/moderna-upsized-convertible-senior-notes-offering BiopharmaWatch en 2026-09-01T00:36:28.377Z Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-minuteclinic-offering-updated-flu-vaccines BiopharmaWatch en 2026-09-01T00:34:57.682Z CVS Pharmacy(R) and MinuteClinic(R) Now Offering Updated Flu Vaccines Nationwide https://www.biopharmawatch.com/news/LOBE/lobe-sciences-upsizes-private-placement BiopharmaWatch en 2026-09-01T00:33:57.459Z Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-fda-approval-mimrylo-polycythemia-vera BiopharmaWatch en 2026-09-01T00:33:34.891Z Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera https://www.biopharmawatch.com/news/LOBE/lobe-sciences-new-cfo-appointment BiopharmaWatch en 2026-09-01T00:33:21.802Z Lobe Sciences Expands Leadership Team with New CFO Appointment https://www.biopharmawatch.com/news/TNON/tenon-medical-private-placement-offering BiopharmaWatch en 2026-09-01T00:33:09.752Z Tenon Medical Announces Pricing of $3M Private Placement Offering https://www.biopharmawatch.com/news/BIIB/canadas-drug-agency-recommends-leqembi-reimbursement BiopharmaWatch en 2026-08-31T23:30:47.000Z Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease https://www.biopharmawatch.com/news/TLX/telix-appoints-david-gill-chair BiopharmaWatch en 2026-08-31T22:21:00.000Z Telix Appoints David Gill as Chair https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-soho-2026-presentations BiopharmaWatch en 2026-08-31T22:05:00.000Z Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-epetraborole-polycythemia-vera-soho-2026 BiopharmaWatch en 2026-08-31T22:00:00.000Z AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/IRON/disc-medicine-soho-2026-presentations BiopharmaWatch en 2026-08-31T22:00:00.000Z Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/YDES/yd-bio-limited-financial-results-june-2026 BiopharmaWatch en 2026-08-31T22:00:00.000Z YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-oversubscribed-public-offering BiopharmaWatch en 2026-08-31T21:58:00.000Z Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering https://www.biopharmawatch.com/news/ACET/adicet-bio-inducement-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-08-31T21:39:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-q3-results BiopharmaWatch en 2026-08-31T21:08:00.000Z Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-morgan-stanley-conference-2023 BiopharmaWatch en 2026-08-31T20:30:00.000Z Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-cantor-healthcare-conference BiopharmaWatch en 2026-08-31T20:30:00.000Z Zura Bio to Participate in the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-josh-hexter-ceo-rami-aviram-cfo BiopharmaWatch en 2026-08-31T20:15:00.000Z Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer https://www.biopharmawatch.com/news/ENOV/enovis-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T20:15:00.000Z Enovis to Participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/SIBN/si-bone-presents-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-08-31T20:09:00.000Z SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 https://www.biopharmawatch.com/news/ALGN/quentin-blackford-joins-align-technology-board BiopharmaWatch en 2026-08-31T20:08:00.000Z Quentin Blackford to Join Align Technology Board of Directors https://www.biopharmawatch.com/news/VIR/vir-biotechnology-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/NPCE/neuropace-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-hc-wainwright-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/KYNB/kyntra-bio-reduces-royalty-financing-obligation BiopharmaWatch en 2026-08-31T20:05:00.000Z Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo BiopharmaWatch en 2026-08-31T20:05:00.000Z Inventiva nomme Chris Benecchi au poste de Chief Operating Officer https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo BiopharmaWatch en 2026-08-31T20:05:00.000Z Inventiva Appoints Chris Benecchi as Chief Operating Officer https://www.biopharmawatch.com/news/SYK/stryker-acquires-zurimed-enhance-shoulder-offering BiopharmaWatch en 2026-08-31T20:05:00.000Z Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-labs-sci-210-autism-trial-enrollment BiopharmaWatch en 2026-08-31T20:03:00.000Z SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial https://www.biopharmawatch.com/news/PMVP/pmv-pharma-proposed-public-offering-securities BiopharmaWatch en 2026-08-31T20:02:00.000Z PMV Pharma Announces Proposed Public Offering of Securities https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-08-31T20:01:00.000Z Arcturus Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GRAL/grail-presentation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T20:01:00.000Z GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q1-2027-results BiopharmaWatch en 2026-08-31T20:01:00.000Z Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14 https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-updated-rezatapopt-ovarian-cancer-data BiopharmaWatch en 2026-08-31T20:01:00.000Z PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial https://www.biopharmawatch.com/news/WAT/wellinks-appoints-agwunobi-waters-board-directors BiopharmaWatch en 2026-08-31T19:51:00.000Z Wellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team https://www.biopharmawatch.com/news/LOBE/lobe-sciences-private-placement-august-2026 BiopharmaWatch en 2026-08-31T19:00:00.000Z Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-medicines BiopharmaWatch en 2026-08-31T19:00:00.000Z BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines https://www.biopharmawatch.com/news/HIMS/hims-enters-australia-asia-pacific-expansion BiopharmaWatch en 2026-08-31T19:00:00.000Z Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market https://www.biopharmawatch.com/news/EXEL/exelixis-patent-litigation-update-msn-laboratories BiopharmaWatch en 2026-08-31T18:30:00.000Z Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-participate-morgan-stanley-conference BiopharmaWatch en 2026-08-31T18:00:00.000Z IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-her2-cancer BiopharmaWatch en 2026-08-31T17:25:00.000Z BeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-her2-cancer-results BiopharmaWatch en 2026-08-31T17:25:00.000Z Samenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker https://www.biopharmawatch.com/news/TNON/wallachbeth-capital-closes-tenon-medical-private-placement BiopharmaWatch en 2026-08-31T16:30:00.000Z WallachBeth Capital Announces Closing of Tenon Medical https://www.biopharmawatch.com/news/BTMD/biotecanada-2026-gold-leaf-award-winners BiopharmaWatch en 2026-08-31T14:49:00.000Z BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem https://www.biopharmawatch.com/news/HLF/herbalife-reaffirms-guidance-2026 BiopharmaWatch en 2026-08-31T13:54:00.000Z Herbalife Reaffirms Third Quarter and Full Year 2026 Guidance https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-ziihera-gea-treatment BiopharmaWatch en 2026-08-31T13:07:00.000Z Riassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T13:00:00.000Z Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/AIM/aim-immunotech-patent-ampligen-pembrolizumab-cancer BiopharmaWatch en 2026-08-31T12:51:00.000Z AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 https://www.biopharmawatch.com/news/PFSA/profusa-compliance-nasdaq-requirement BiopharmaWatch en 2026-08-31T12:50:00.000Z Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement https://www.biopharmawatch.com/news/DARE/dare-bioscience-nih-funding-dare-ptb2-preterm-birth BiopharmaWatch en 2026-08-31T12:44:00.000Z Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth https://www.biopharmawatch.com/news/ONMD/onemednet-iRWD-platform-ai-drug-development BiopharmaWatch en 2026-08-31T12:35:00.000Z OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company https://www.biopharmawatch.com/news/LXRX/lexicon-sotagliflozin-soloist-whf-analysis BiopharmaWatch en 2026-08-31T12:30:31.000Z Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-appoints-michaela-levin-cbo BiopharmaWatch en 2026-08-31T12:30:29.000Z Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer https://www.biopharmawatch.com/news/SUPN/chloe-kim-qelbree-adhd-awareness BiopharmaWatch en 2026-08-31T12:30:00.000Z Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-pf614-mpar-102-study-completion BiopharmaWatch en 2026-08-31T12:30:00.000Z Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-september-investor-conference BiopharmaWatch en 2026-08-31T12:30:00.000Z Allogene Therapeutics Announces Participation in September Investor Conference https://www.biopharmawatch.com/news/HYPR/hyperfine-lake-street-conference-participation BiopharmaWatch en 2026-08-31T12:15:00.000Z Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference https://www.biopharmawatch.com/news/AMRN/amarin-esc-congress-2026-findings BiopharmaWatch en 2026-08-31T12:15:00.000Z Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-ttx-mc138-breast-cancer-study BiopharmaWatch en 2026-08-31T12:05:00.000Z TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis https://www.biopharmawatch.com/news/KLRS/kalaris-present-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T12:00:09.000Z Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-morgan-stanley-conference BiopharmaWatch en 2026-08-31T12:00:07.000Z OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GEHC/ge-healthcare-photonova-spectra-ce-mark BiopharmaWatch en 2026-08-31T12:00:00.000Z GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access https://www.biopharmawatch.com/news/ABBV/abbvie-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-michael-grasher-cfo BiopharmaWatch en 2026-08-31T12:00:00.000Z Teladoc Health Appoints Michael Grasher as Chief Financial Officer https://www.biopharmawatch.com/news/AEON/aeon-biopharma-lake-street-capital-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-bezisterim-long-covid BiopharmaWatch en 2026-08-31T12:00:00.000Z BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID https://www.biopharmawatch.com/news/XAIR/beyond-air-fda-breakthrough-lungfit-go-ntm-pd BiopharmaWatch en 2026-08-31T12:00:00.000Z Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-fda-type-d-meeting-cad-1005 BiopharmaWatch en 2026-08-31T12:00:00.000Z Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PTGX/fda-approval-mimrylo-rusfertide-polycythemia-vera BiopharmaWatch en 2026-08-31T12:00:00.000Z US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-canada BiopharmaWatch en 2026-08-31T11:55:00.000Z Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-opioid-overdose-awareness BiopharmaWatch en 2026-08-31T11:54:00.000Z Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day https://www.biopharmawatch.com/news/AGEN/agenus-participate-september-investor-conferences BiopharmaWatch en 2026-08-31T11:30:00.000Z Agenus to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/KPTI/karyopharm-submits-snda-fda-xpovio-ruxolitinib-myelofibrosis BiopharmaWatch en 2026-08-31T11:30:00.000Z Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-ndas-qtorin-rapamycin BiopharmaWatch en 2026-08-31T11:30:00.000Z Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-08-31T11:00:07.000Z Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-conference-participation-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-financial-results-h1-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-q2-2026-results-update BiopharmaWatch en 2026-08-31T11:00:00.000Z BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LH/labcorp-global-trial-connect-enhancements BiopharmaWatch en 2026-08-31T11:00:00.000Z Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-summit-phase-3-trial-axs-05 BiopharmaWatch en 2026-08-31T11:00:00.000Z Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation https://www.biopharmawatch.com/news/ASND/ascendis-biomarin-global-settlement-yuviwel BiopharmaWatch en 2026-08-31T11:00:00.000Z Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) https://www.biopharmawatch.com/news/TELA/tela-bio-coo-cfo-transition-cost-reduction BiopharmaWatch en 2026-08-31T11:00:00.000Z TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative https://www.biopharmawatch.com/news/HLF/herbalife-ceo-transition-stephan-gratziani BiopharmaWatch en 2026-08-31T10:50:00.000Z Herbalife Announces Planned CEO Transition https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-ziihera-data-her2-cancer BiopharmaWatch en 2026-08-31T10:00:00.000Z BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-fda-type-c-meeting-ide849 BiopharmaWatch en 2026-08-31T10:00:00.000Z IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer https://www.biopharmawatch.com/news/NUTX/nutex-health-hospitals-community-honors-q2-2026 BiopharmaWatch en 2026-08-31T09:30:00.000Z Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026 https://www.biopharmawatch.com/news/SBFM/health-canada-approves-sunshine-biopharma-atenolol BiopharmaWatch en 2026-08-31T09:00:00.000Z Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions https://www.biopharmawatch.com/news/UTMD/femcare-acquires-orion-medical-supplies-uk BiopharmaWatch en 2026-08-31T09:00:00.000Z Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK https://www.biopharmawatch.com/news/NNVC/nanoviricides-nv-387-clinical-trials-measles-treatment BiopharmaWatch en 2026-08-31T08:30:00.000Z While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles https://www.biopharmawatch.com/news/ALVO/alvotech-fda-review-avt80-biosimilar BiopharmaWatch en 2026-08-31T08:30:00.000Z Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations https://www.biopharmawatch.com/news/AMGN/amgen-repatha-reduces-death-risk-heart-attack-stroke BiopharmaWatch en 2026-08-31T07:18:00.000Z AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-31 BiopharmaWatch en 2026-08-31T07:15:24.149Z Biotech Catalysts to Watch: Key Developments Ahead in Q4 2026 https://www.biopharmawatch.com/news/BMRN/biomarin-settlement-ascendis-yuviwel-royalties BiopharmaWatch en 2026-08-31T06:00:00.000Z BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data-rnai-therapy BiopharmaWatch en 2026-08-31T04:46:00.000Z Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-rnai-therapy-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Riassunto: Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-transthyretin-silencing-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Resumen: Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans... https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-rnai-ttr-silencing BiopharmaWatch en 2026-08-31T04:35:00.000Z Samenvatting: Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-oversubscribed-public-offering BiopharmaWatch en 2026-08-31T00:00:00.000Z Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ... https://www.biopharmawatch.com/news/JAZZ/ziihera-chemotherapy-survival-benefit-her2-advanced-gea BiopharmaWatch en 2026-08-31T00:00:00.000Z Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial... https://www.biopharmawatch.com/news/LLY/lilly-taltz-zepbound-phase-3b-results BiopharmaWatch en 2026-08-31T00:00:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically... https://www.biopharmawatch.com/news/BHC/bausch-health-launches-fraxel-ftx-australia BiopharmaWatch en 2026-08-31T00:00:00.000Z Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today... https://www.biopharmawatch.com/blog/biotech-stocks-hedge-funds-are-buying-q2-2026 BiopharmaWatch en 2026-08-30T22:41:03.361Z The 28 Biotech Stocks Hedge Funds Are Buying and Holding in 2026 (Q2 13F Special Report)